This study demonstrates that incorporating IL-28B as a molecular adjuvant significantly enhances the immunogenicity of a bivalent DNA vaccine (pVAX-GRA28/pVAX-GRA83) against toxoplasmosis. This evidence concerns the gene IFNL3 and toxoplasmosis.